AEON Biopharma Analyst Ratings
Buy Rating Affirmed for AEON Biopharma on Strategic Biosimilar Pathway and Promising Phase 3 Study Prospects
AEON Biopharma Analyst Ratings
Buy Rating Affirmed for AEON Biopharma: Strategic Cost-Cutting and ABP-450's Broad Market Potential
AEON Biopharma Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)
AEON Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
AEON Biopharma Analyst Ratings
Analysts Have Conflicting Sentiments on These NA Companies: Digital Realty (DLR) and AEON Biopharma (AEON)
AEON Biopharma Analyst Ratings
H.C. Wainwright Initiates a Buy Rating on AEON Biopharma (AEON)
No Data